• Free Consultation
  • Free IP Audit
  • International Brand Protection
  • About
  • Careers
  • Global IP Blogs
  • Contact
  • Login
Lexprotector.com
+1 – 888 890 6411 [email protected]
  • Trademark
    • Trademark Search
      • Indian Trademark Search
      • USA Trademark Search
      • EU Trademark Search
      • UK Trademark Search
      • Canada Trademark Search
      • Australia Trademark Search
      • New Zealand Trademark Search
    • Trademark Registration
      • Indian Trademark Registration
      • USA Trademark Registration
      • EU Trademark Registration
      • UK Trademark Registration
      • Canada Trademark Registration
      • Australia Trademark Registration
      • New Zealand Trademark Registration
    • Trademark Monitoring
      • Indian Trademark Monitoring
      • USA Trademark Monitoring
      • EU Trademark Monitoring
      • UK Trademark Monitoring
      • Canada Trademark Monitoring
      • Australia Trademark Monitoring
      • New Zealand Trademark Monitoring
    • Trademark Consultation
      • Indian Trademark Consultation
      • USA Trademark Consultation
      • EU Trademark Consultation
      • UK Trademark Consultation
      • Canada Trademark Consultation
      • Australia Trademark Consultation
      • New Zealand Trademark Consultation
  • Patent
    • Patent Search
      • Prior Art Search
      • Freedom to Operate Search
      • Utility Patent Search
    • Patent Drafting
      • USA Provisional Patent Drafting
      • USA Non-Provisional Patent Drafting
      • Indian Provisional Patent Drafting
      • Indian Complete Specification Drafting
    • Patent Filing
      • USA Provisional Patent Filing
      • USA Non-Provisional Patent Filing
      • Indian Provisional Patent Filing
      • Indian Complete Specification Filing
    • Patent Consultation
      • Patent Consultation
      • Utility Patent Consultation
      • Design Patent Consultation
    • Design Patent
      • Design Patent Search
      • EU Design Patent Filing
      • USA Design Patent Filing
      • India Industrial Design Filing
  • IP Enforcement
    • Violation Search
    • DMCA Takedown Notice
    • IP Enforcement
      • Copyright Enforcement
      • Trademark Enforcement
      • Utility Patent Enforcement
      • Design Patent Enforcement
    • Amazon Brand Registration
    • Copyright Registration
      • Indian Copyright Registration
      • USA Copyright Registration
  • IP Management
    • IP Due Diligence
    • IP Auditing
    • IP Valuation
    • IP Licensing
    • IP Consultation
+1 – 888 890 6411 [email protected]

The pros and cons of Indian Drugs (Prices Control) Order 2013

  • Older
  • Newer

The pros and cons of Indian Drugs (Prices Control) Order 2013

The Department of Pharmaceutical in the Union Ministry of Chemicals and Fertilizers gazetted the Drugs (Prices Control) Order 2013 on May 16th, 2013. The new pricing policy will replace the previous drug pricing policy of 1995. It will be effective from 1st July, 2013. The new order will control the pricing of 348 drug formulations mentioned in the list of National List of Essential Medicines (NLEM), 2011 instead of 74 drugs or formulations listed in the previous policy. The 348 drugs are defined in terms of specified strength. Actually, about 650 drugs in pharmaceutical selves under 27 therapeutic categories will come under the scanner of the price control authority. The new policy has authorized the National Pharmaceutical Pricing Authority (NPPA) to control the prices of the listed drugs. Anti-cancer drugs including the much talked about Zidovudine-Lamivudine-Nevirapine , Imatinib, Carboplatin, Dacarbazine, Daunorubicn, Oxaliplatin and Chlorambucil are some of the drugs that have been included in the new list.

 

drug-policy_1

 

The Union Government has taken a long time to formulate the new drug policy due to internal conflict between the ministries of health and chemical and fertilizers. In the last meeting, Ministry of Finance also raised some objections. The Government was forced to issue the new policy due to a stern notification from Supreme Court. The patented drugs will not come under the recent policy. A Government appointed committee recommended bringing the patented drugs under price control policy. The government did not accept the proposal. However, government has assured that they will take a decision on this issue within a short period.

 

drug-policy

 

In the previous regime, the pricing of the drugs were fixed on the basis of manufacturing costs declared by the drug manufacturers. Now, ceiling prices would be calculated taking simple average of the sum of prices of all the drug brands and genetic versions of the medicines having a market share equal to or more than 1%. The calculated result will be defined as “Average price to retailer”. If we assume the value of the average price of the retailer is X, then the ceiling price would be
Z=X.(1+Y/100), assuming that
Z=Ceiling price
X=Average price
Y= % Margin to retailer and its value =16
The retail price of the new drug which is not available in the domestic market will be calculated on the basis of Pharmacoeconomic. It is a scientific process of drug pricing comparing the value of one drug with another drug or therapy of the same group.

 

 

The new policy received a warm welcome from all section of people and health activists. Indian drug manufacturers also hailed the decision. According to experts, the new policy reduces the price of the essential drugs from 30% to 60% depending on the variation of the drugs. As most of the Indian patients spend their own money for their treatment, they will get a great relief by the new drug policy. However, health activists are sceptical about the utility of the bill. According to their opinion, many essential drugs were not listed in “NLEM”. The list was last updated in 2003. They demanded immediate revision of the list. They also said that the pricing on the basis manufacturing cost reduces the prices of drug. They have cited the example recent ruling of the court in the case of Cipla vs Novartis regarding cancer drug Glivec.

 

 

We think that the new drug pricing is an initial step to provide a better healthcare facility to the people of India. For more information, you may contact Lex Protector.

 

 

  • Categories
    Patent
  • Author

    Lex Protector

Contents

Get Monthly

Global IP Updates

Join our community of over 10,000 subscribers and receive monthly updates on the latest IPR news and changes from around the globe.

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *

Related Posts

The Curious Case of ‘Sorafenib Tosylate’

The Cause and Effect of Patent Trolling

The benefits of patent insurance

Subscribe Us

Quick Links

  • Utility Patent Search
  • Patent Drafting
  • Patent Consultation
  • Design Patent Search
  • Portfolio
  • Partner Portal Login
  • Global IP Blogs
  • Todays Trademark Blog
  • Todays Patent Blog

Services

  • USA Trademark Registration
  • UK Trademark Registration
  • EU Trademark Registration
  • Indian Trademark Registration
  • Australia Trademark Registration
  • New Zealand Trademark Registration
  • Canada Trademark Registration
  • Copyright Registration
  • DMCA Takedown Notice

Contact Us

  • [email protected]
  • +1 – 888 890 6411 +1 (833) 535-9144 (FAX)
  • 16192 Coastal Highway, Lewes, Delaware 19958, USA

In India - Bhubaneswar | Ahmedabad | Bangalore | Guwahati | Mumbai

International - United States | United Kingdom | Australia | Estonia

© 2012-25 LEX PROTECTOR. All rights reserved

  • Terms & Conditions
  • Privacy Policy
  • Disclaimer
  • DMCA

Quick The pros and cons of Indian Drugs (Prices Control) Order 2013